Factoring in Safety Considerations With IV Iron Products

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility requirements for administration, while emphasizing that modern formulations have significantly improved safety profiles compared with older products.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

Now Viewing

EP: 8.Factoring in Safety Considerations With IV Iron Products

EP: 9.Adverse Effects Associated With Hypophosphatemia

EP: 10.Clinical Impact of Hypophosphatemia

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• How does the presence of a black box warning on certain IV iron products influence your clinical decision-making process?

Related Videos

Related Content

Advertisement

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 8th 2025

Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment

Brooke McCormick

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).

March 8th 2025

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Brooke McCormick

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes.

Related Content

Advertisement

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 8th 2025

Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment

Brooke McCormick

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).

March 8th 2025

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Brooke McCormick

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes.